A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

This study is looking for men aged 18 and over who have a confirmed diagnosis of prostate cancer that has not spread to other parts of the body but is no longer responding to standard hormone treatments. You would typically need to show a continuous rise in a blood marker called PSA, even while on hormone therapy.

To join, your doctors must have already decided that darolutamide is the right treatment for you, based on their usual practice. You would also need to have imaging scans that confirm your cancer has not spread. If you've been on similar hormone-blocking medicines like enzalutamide or apalutamide before, there are specific rules about how long you used them and whether any side effects have settled.

You wouldn't be able to join if you're taking part in another study with experimental treatments, if darolutamide isn't suitable for you based on its instructions, or if you've already taken darolutamide for more than three days before deciding to join this study. Also, if you had a very long previous treatment (over a year) with enzalutamide or apalutamide, you would not be eligible.

Because this is an 'observational' study, taking part mainly involves allowing researchers to collect information from your existing medical records and during your routine doctor's appointments. You won't be given any extra medicines or treatments specifically for the study itself; you'll receive your darolutamide as prescribed by your doctor. The study will track your health outcomes, such as your PSA levels, how you're feeling, and any side effects, over a period of time. The total duration of your participation would depend on your individual treatment plan and how long your doctor determines you should stay on darolutamide.